Compare AbCellera Biologics Inc (ABCL) vs Commvault Systems Inc (CVLT) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Commvault Systems (CVLT) trades at $150.05, up 0.05% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.28 exceeding the $1.09 estimate. However, high valuation multiples like a P/E of 94.97 and P/B of 829.37 suggest premium pricing. Recent news highlights a class action lawsuit filed against the company, alongside positive product announcements including a #1 ranking in Gartner's 2026 backup solutions report.

Outlook remains mixed with analyst consensus leaning bullish (54.55% buy ratings) and a $128.75 price target below current levels. Key risks include the ongoing securities litigation and elevated valuations, while opportunities lie in continued earnings momentum and market leadership in data protection. Investors should weigh legal overhangs against fundamental strength.